LIFEWORKS
8.9.2021 11:02:06 CEST | Business Wire | Press release
LifeWorks, a leading provider of digital and in-person total wellbeing solutions, has announced the acquisition of Ascender, a leading psychological services provider in the field of employee health and wellbeing.
Key highlights of the acquisition include:
- Headquartered in the Netherlands, Ascender’s highly experienced team of 38 employees and approximately 40 freelancers will join LifeWorks and continue to operate out of its 25 locations across the Netherlands, with existing clients seeing their services continue uninterrupted.
- As Ascender is integrated into LifeWorks global operations, it will operate in the Netherlands on a largely standalone basis, servicing clients throughout the Benelux region.
- Ascender operated first as a combination of network partners 25 years ago and merged to become Ascender in 2009. It is one of the most respected providers in the corporate wellbeing market in the Netherlands and has a strong roster of approximately 150 clients with an average tenure of 10 years.
- The acquisition will leverage the skills, knowledge and experience Ascender’s teams and services that include psychological services related to health@work, employee assistance programmes, counselling, and training through a team of highly credentialed psychologists, while giving Ascender access to LifeWorks clinical best practices, digital technology and worldwide presence.
- With Ascender’s strong track record of growth, local knowledge and clinical expertise, the move will allow LifeWorks to continue to expand its total wellbeing solutions to domestic European markets, and harness its existing relationships with insurance providers, hospitals and care companies as well as (multi)nationals working out of the Netherlands post-Brexit.
Comments from Philip Mullen, managing director, United Kingdom and Europe at LifeWorks:
“Throughout the pandemic we have witnessed a huge appetite amongst multinationals and local companies to support the total wellbeing of employees that are now spread across the world. The acquisition of Ascender will not only strengthen our presence in this region, but in addition, given Ascender offers a full suite of clinical expertise and research, our hope is that the company’s insight on psychological wellbeing can further enhance our customer offering on a global level.”
Comments from Moniek Vossenaar, managing director, Ascender:
“Joining LifeWorks represents an important step for Ascender’s growth, the services we provide and the opportunities for our employees. The companies have a shared goal to improve the total wellbeing of our clients’ employees, and shared values of long-term relationships, treating others the way we want to be treated, and being innovative and entrepreneurial. We’re positive this acquisition will be beneficial to both companies and all parties involved.”
This acquisition represents approximately one per cent of LifeWorks revenue and is not expected to have a material impact on the company’s financial performance in 2021.
About LifeWorks
LifeWorks is a world leader in providing digital and in-person solutions that support the total wellbeing of individuals. We deliver a personalised continuum of care that helps our clients improve the lives of their people and by doing so, improve their business.
About Ascender
Founded in 2009, Ascender is one of the top three players in the corporate wellness market in the Netherlands and has a strong roster of approximately 150 clients with an average tenure of 10 years. Headquartered in the Netherlands, Ascender hash 25 locations across the country, 38 employees and approximately 40 freelancers. The company offers psychological services related to health@work, EFAP, counselling, and training/coaching through a team of psychologists, on a fee for service basis.
ID-CORP, ID-MH, ID-UK
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005404/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB to Acquire Kelvion, Expanding its Role Across Data Center Infrastructure31.8.2026 12:50:00 CEST | Press release
Scalable, energy-efficient and reliable thermal management technologies will optimize operating performance in increasingly complex data centers and industrial systems SLB (NYSE: SLB) today announced it has signed an agreement to acquire Kelvion, a global provider of thermal management and heat exchange technologies. The acquisition strengthens SLB's Data Center Solutions business with critical thermal management technologies and expands the company's role in data center infrastructure, which is one of the world’s fastest-growing industrial and technology markets. “AI is driving the most significant infrastructure investment cycle in our lifetime,” said Olivier Le Peuch, chief executive officer of SLB. “This transaction accelerates our ambition to become an industrial technology partner to the data center industry and help customers address the growing infrastructure complexity required to scale AI. Kelvion advances our path toward more integrated data center infrastructure solutions,
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release
Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA
GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
